• FirefoxInstall the new Firefox »
  •  Dow Down0.45% Nasdaq Down0.49%

    Hyperion Therapeutics, Inc. (HPTX)

    29.55 Up 1.82(6.56%) Feb 27, 4:00PM EST
    |After Hours : 29.54 Down 0.01 (0.02%) Feb 27, 4:36PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Hyperion Therapeutics, Inc.
    2000 Sierra Point Parkway
    Suite 400
    Brisbane, CA 94005
    United States - Map
    Phone: 650-745-7802
    Fax: 650-871-7029
    Website: http://www.hyperiontx.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    Hyperion Therapeutics, Inc., a commercial biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. The company’s products include RAVICTI, which is used as a nitrogen-binding agent for chronic management of adult and pediatric urea cycle disorder (UCD) patients greater than two years of age, who cannot be managed by dietary protein restriction and/or amino acid supplementation alone; and BUPHENYL, an FDA-approved therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Hyperion Therapeutics, Inc.

    Corporate Governance 
    Hyperion Therapeutics, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 8. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Donald J. Santel M.S., B.S.E., 54
    Chief Exec. Officer, Pres and Director
    Mr. Jeffrey S. Farrow , 53
    Chief Financial Officer and Principal Accounting Officer
    Ms. Ashley C. Gould , 40
    Chief Legal & Compliance Officer, Sr. VP of Gov. Affairs and Sec.
    Ms. Natalie C. Holles , 42
    Sr. VP of Corp. & Bus. Devel.
    Mr. Bruce Frederick Scharschmidt M.D., 69
    Chief Medical Officer and Sr. VP
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders